Benzylfuranylpropylaminopentane

(-)-BPAP, -)-1-(Benzofuran-2-yl)-2-propylaminopentane, or BFPAP

  BPAP is a drug that was developed for use in delaying the onset/development of Parkinson's and Alzheimer's, similar to deprenyl or selegiline. This compound is available via research chemical vendors.
BPAP is unique as it is a catecholamine activity enhancer; acting upon serotonin, norepinephrine, and dopamine. This means it enhances the release of these neurotransmitters in response to stimuli, as opposed to just causing an uncontrolled release as with drugs like cocaine and mdma. It also exhibits neuroprotective properties. 
BPAP acts similar to (-)deprenyl however it is tryptamine derived as opposed to phenylethylamine derived. It is a more potent catecholamine enhancer but is also a much weaker inhibitor of MAO-A when compared to (-)deprenyl.